This Company has developed a Personalized App to Fight Cancer By Clara Rodríguez Fernández 1 minutemin November 4, 2016 -Updated: onJune 22, 2022 1 minutemin Share WhatsApp Twitter Linkedin Email Newsletter Signup - Under Article / In Page"*" indicates required fieldsX/TwitterThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* We say goodbye to the good weather in Spain and cross the Pyrenees to visit Charleroi, an industrial city south of Brussels. There, we find OncoDNA, a young company striving to change the oncology field using DNA.City: Charleroi, BelgiumFounded: 2012Employees: 11 – 50Financial data: €7.7M raised in September to expand into the global marketJean-Pol Detiffe, CEOMission: OncoDNA uses next-generation sequencing to analyze major DNA mutations in cancer and match the patient with a personalized treatment option. The coolest part is that the whole process can be controlled via a mobile app with a pretty neat design. On April, the company launched OncoTRACE, the first non-invasive personalized test to monitor tumor progression.Comment: OncoDNA could pass for the smaller sibling of Foundation Medicine in the US. Jean-Pol Detiffe, its CEO, will be speaking at Labiotech Refresh this November. Don’t miss it! Organoids in cancer research: Paving the way for faster drug development across cancer indications This webinar explores how patient-derived organoids (PDOs) are redefining oncology research. Discover how advanced, well-characterized models empower researchers to streamline candidate selection, accelerate orphan drug programs, and deliver transformative therapies to patients faster than ever. Watch now Explore other topics: BelgiumCancerDiagnosticsNext generation sequencingOncoDnaPrecision medicine ADVERTISEMENT